Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Senate Medicaid Supplemental Rebate Amendment May Block PhRMA Suits

Executive Summary

An amendment to generic drug legislation in the Senate would eliminate the Pharmaceutical Research & Manufacturers of America's ability to challenge state Medicaid programs' use of supplemental drug rebates for residents not eligible for Medicaid

Related Content

GSK Selling Direct To Canadian Pharmacies, Auditing Orders To Curb Imports
Michigan Plans Multi-State Drug Purchasing Pool Under Gov.-Elect Granholm
Reimport Bills Would Require “Extraterritorial” Action By FDA – Crawford
Michigan Rx Rebate Program Decision Should Be Left To HHS, DoJ Tells Court
Multi-State Rx Group To Start Additional Rebate Negotiations In October
PhRMA Marketing Code Is Basis Of Legislation Proposed By Sen. Clinton
Rx Rebates, Gifts To Physicians Would Be Public Under Torricelli Proposal
House Examines Medicare Rx Alternatives: Drug Reimportation To “Move”
Compromise Medicare Rx Benefit Will Be Next Step For Senate, Daschle Says
PhRMA Takes Michigan Rebate Dispute To Federal Court Ahead Of Payments



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts